Navigation Links
InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
Date:4/23/2013

enter, randomized trial, comparing both bare metal and drug eluting stents, the current therapy for STEMI patients."

The FDA trial will be known as The MASTER II (MGuard™ for Acute ST Elevation Reperfusion), the second in a series of clinical studies intended to both validate the effectiveness of the MGuard™ EPS platform, as well as achieve registration with the appropriate regulatory authorities worldwide.

InspireMD's MGuard™ EPS technology previously yielded positive results in the MASTER I findings, which revealed a statistically and clinically significant acute advantage of MGuard™ EPS with regard to ST segment resolution. As a result, MGuard™ EPS may hold the potential to lower the incidence of adverse events and prolong the survival of patients suffering from acute myocardial infarction.

About InspireMD's MGuard™ EPS Technology

In stroke and acute heart attack patients, the plaque or thrombus is unstable and often breaks up as a stent is implanted causing downstream blockages, some of which can be fatal, in a significant portion of heart attack patients.

The MGuard™ EPS stent system is integrated with a precisely engineered micro net mesh designed to prevent the unstable arterial plaque and thrombus (clots) that cause these blockages from breaking off. The mesh is designed to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ EPS is CE Mark approved. MGuard™ EPS, however, is not approved for sale in the U.S. by the FDA.

About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Forward-looking Statements
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)... 2014  ResMed (NYSE: RMD ), a pioneer ... to design complete sleep apnea solutions specifically for women, is ... of a good night,s sleep. The Better ... feeling tired is just part of living a busy life. ... critical pillar of health, essential to not only living an ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems (NYSE: ... report results for the fourth quarter of fiscal year ... October 22, 2014.  The news release will be followed ... 2:00 p.m. PT.  The news release and a link ... the company website at: www.varian.com/investor .  To access ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) ... -- may face an increased risk of dying in the next ... 3,000 older Americans, researchers found those who were unable to detect ... times as likely to die in the next five years, versus ... -- the inability to distinguish odors -- was a bigger predictor ...
(Date:10/2/2014)... scientists at The University of Nottingham could lead to ... , A drug resulting from the research, published in ... new hope to sufferers of chronic pain conditions such ... are currently available. , The work, led by Dr ... in collaboration with David Bates, Professor of Oncology in ...
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... the Engineering and Physical Sciences Research Council (EPSRC) ... vital industrial control systems which run, for example, ... the rail network. , The research will ... malware infiltrating the systems behind our critical national ... Industrial Control Systems (RITICS), based at Imperial College ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... who cares for patients with cancer at The Children,s Hospital ... Junior Faculty Award in Pediatric Oncology. The American Society of ... award during its annual meeting, occurring June 1-5 in Chicago. ... B. Nachman, a pediatric oncologist and Professor of Pediatrics at ...
... TUESDAY, May 8 (HealthDay News) -- Eating too quickly may ... Researchers from Lithuania compared 234 people with type 2 ... those who gobble down their food were 2.5 times more ... while eating. Study participants with diabetes also were more ...
... Branch at Galveston researchers have discovered that a drug ... also have another important use: treating one of the ... rat and cell-culture experiments, the scientists found that metformin, ... in type 2 diabetes, also substantially reduced the effects ...
... physicians, fees under Medicare which in turn influence ... will pay doctors -- the Centers for Medicare and ... American Medical Association advisory panel. A study led by ... Public Health, found that the Medicare and Medicaid agency ...
... Reporter , MONDAY, May 7 (HealthDay News) -- Those suffering ... their symptoms, but a cure has yet to be found. ... may help patients suffer a little less, but side effects ... preparations impact symptoms of the common cold, there is currently ...
... -- The Medical Publishing Insights and Practices (MPIP) ... editors to characterize the persistent and perceived credibility ... potential approaches to resolve it. This unique round ... Recommendations for Closing the Credibility Gap in Reporting ...
Cached Medicine News:Health News:Diabetes drug could treat leading cause of blindness 2Health News:AMA committee recommendations on doctor fees set by Medicare are followed 9 times out of 10 2Health News:Zinc Pills May Shorten Colds, Analysis Suggests 2Health News:Journals and pharma collaborate on new recommendations 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: